
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Winston-Salem, N.C. - Separate studies involving atopic dermatitis drugs tacrolimus (Protopic) and pimecrolimus (Elidel) show the topical immunomodulators (TIMs) are safe and effective for off-label use on children under age 2.